newsfilter
← Latest News
PR Newswire·

Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST

  • BioArctic AB (publ) will publish its second quarter 2026 report (April-June) on Wednesday, August 26, 2026, at 8:00 a.m. CEST.
  • A webcast in English will follow the report release on August 26 at 9:30 a.m. CEST, featuring CEO Gunilla Osswald, CFO Anders Martin-Löf, \& colleagues for a presentation \& Q\&A session.
  • Investors can submit written questions via the webcast link \& access the teleconference for verbal questions after registering.
  • The webcast will be available on demand on BioArctic's corporate website post-presentation.
  • BioArctic AB is a Swedish biopharma company developing treatments for neurodegenerative diseases, including Leqembi® (lecanemab) for Alzheimer's disease, developed with partner Eisai.
  • The company utilizes its proprietary BrainTransporter™ technology to enhance antibody delivery across the blood-brain barrier for its research portfolio targeting Parkinson's disease, ALS, \& Alzheimer's disease.
  • BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap.
  • Contact persons for further information are Oskar Bosson, Chief Investor Relations \& Communications Officer, \& Jenny Ljunggren, External Communications \& Investor Relations Manager.